New drug cocktail shows promise in slowing uterine cancer before surgery

NCT ID NCT04049227

Completed Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested two drugs, abemaciclib and letrozole, given before standard hysterectomy in 27 women with endometrial cancer. The goal was to see if the combination could slow cancer cell growth by measuring changes in a protein called Ki-67. The study was small and focused on biological markers, not long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib and letrozole
What this could lead to: If successful, this could point toward a new drug combination to slow endometrial cancer growth before surgery.
What could go wrong: This is a very early, small pilot study with only 27 participants. It only measures short-term biomarker changes, not long-term outcomes like survival or recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial endometrioid adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA

Contacts and locations

Locations

Northwestern University

Chicago, Illinois, 60611, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.